SCHEMBL7915369

SCHEMBL7915369

O=C(O)c1ccc2cccc(-c3c(F)ccc(O)c3F)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2D Q9UNK4 1/20 0.46
TTR P02766 2/20 0.41
HSD17B14 Q9BPX1 4/20 0.40
MCL1 Q07820 1/20 0.40
ACMSD Q8TDX5 1/20 0.40
KDM4E B2RXH2 2/20 0.39
PTPN1 P18031 1/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA6 P23280 2/20 0.39
CA9 Q16790 2/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
CA4 P22748 1/20 0.39
PTGS2 P35354 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7921825 0.90 PLA2G2D (0.46) PLA2G2DTTRHSD17B14MCL1ACMSD
SCHEMBL7915371 0.87 PLA2G2D (0.44) PLA2G2DTTRHSD17B14MCL1ACMSD
SCHEMBL7923112 0.86 PLA2G2D (0.48) PLA2G2DTTRHSD17B14PTPN1CA12
SCHEMBL16502418 0.86 TTR (0.48) PLA2G2DTTRHSD17B14MCL1ACMSD
SCHEMBL7918210 0.86 PLA2G2D (0.52) PLA2G2DTTRPTPN1HSD17B10CA12
SCHEMBL16502603 0.85 LCK (0.47) HSD17B14KDM4ELMNAHSD17B10CA12
SCHEMBL7918480 0.85 PLA2G2D (0.51) PLA2G2DTTRHSD17B14MCL1ACMSD
SCHEMBL16502614 0.84 PLA2G2D (0.46) PLA2G2DTTRPTPN1CA12CA1
SCHEMBL7918249 0.83 HTR5A (0.49)
SCHEMBL16502500 0.82 PLA2G2D (0.49) PLA2G2DTTRPTPN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
WO-2010090304-A1 ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A PLA2G2D 841/4885TTR 2550/4885HSD17B14 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.